IMMX
Immix Biopharma Inc
11.00$
-6.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -11.3% | +72.4% | -16.0% | -12.8% | -8.7% | -13.3% | -21.4% | +28.4% | +422.1% | -8.6% | +149.5% | |
| – | -11.4% | +66.3% | -17.0% | -16.7% | -11.2% | -16.9% | -26.5% | +34.6% | +510.4% | -8.9% | +153.4% | |
| – | -10.6% | +67.4% | -18.2% | -17.9% | -10.2% | -10.0% | -26.9% | +37.0% | +489.0% | -15.6% | +184.5% | |
| – | -10.6% | +67.4% | -18.2% | -17.9% | -10.2% | -10.0% | -26.9% | +37.0% | +529.6% | -9.8% | +156.2% | |
| – | +79.6% | +72.7% | -2.2% | -0.2% | -0.1% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +31.7% | +80.4% | -26.4% | +53.5% | +27.7% | +6.2% | +6.6% | +7.6% | -6.5% | +3.7% | -11.0% | |
| – | +31.7% | +52.0% | -31.0% | +68.2% | +32.3% | +7.1% | +7.5% | +8.4% | -6.8% | +4.2% | -11.7% | |
| – | – | – | +41.1% | +29.7% | +4.0% | +4.0% | +3.9% | +100.5% | -1.4% | -10.0% | -11.4% | |
| – | -8.5% | +145.1% | -33.2% | +40.1% | +63.9% | +6.6% | +15.2% | +6.6% | -22.8% | -13.1% | +11.6% | |
| – | -17.0% | +70.2% | -14.4% | -26.5% | -24.5% | -27.6% | -51.5% | +77.6% | +1,034.9% | -10.1% | +171.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.2% | +17.6% | +22.8% | +2.2% | -6.4% | +7.8% | +1.0% | +6.5% | +19.9% | +44.6% | +15.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.